Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
3SBio ( (HK:1530) ) has issued an announcement.
3SBio Inc. has outlined the terms of reference for its Nomination Committee, which is responsible for identifying and recommending suitable candidates for the company’s board of directors. The committee, comprising a majority of independent non-executive directors, plays a crucial role in overseeing board performance evaluations and developing nomination guidelines, thereby impacting the company’s governance and strategic direction.
The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.
More about 3SBio
3SBio Inc. is a company incorporated in the Cayman Islands, operating within the pharmaceutical industry. It focuses on developing, manufacturing, and marketing biopharmaceutical products, primarily targeting treatments for cancer, autoimmune diseases, and nephrology.
Average Trading Volume: 59,718,969
Technical Sentiment Signal: Buy
Current Market Cap: HK$54.33B
See more insights into 1530 stock on TipRanks’ Stock Analysis page.